Hematologic and molecular response in relation to initial BCR-ABL mutational status
| Mutational status at study start . | Complete hematologic response . | Nested PCR negative . | |
|---|---|---|---|
| Imatinib ind. N (%) . | CTX ind. N (%) . | N (%) . | |
| KD mutation | 9/9 (100) | 5/8 (62.5) | 5/17 (29.4) |
| Unmutated | 9/10 (90) | 6/11 (54.5) | 7/21 (33.3) |
| Mutational status at study start . | Complete hematologic response . | Nested PCR negative . | |
|---|---|---|---|
| Imatinib ind. N (%) . | CTX ind. N (%) . | N (%) . | |
| KD mutation | 9/9 (100) | 5/8 (62.5) | 5/17 (29.4) |
| Unmutated | 9/10 (90) | 6/11 (54.5) | 7/21 (33.3) |
ind. indicates induction; CTX, chemotherapy.